A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

Summary

This is a phase 1, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of Y101D in patients with metastatic or locally advanced solid tumors.

Timeline

Start

2021-08-06

Primary completion

2024-07-05

Completion

2024-09-09

Publications

• Sun H, Chen G, Xue J, Zhang Y, Ma Y, Yang Y, Fang W, Zhao Y, Huang Y, Hong S, Zhou T, Zhao S, Zhou H, Chen X, Li J, Zhang L, Zhao H. Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-beta in patients with advanced solid tumors. Oncologist. 2026 May 8;31(6):oyag133. doi: 10.1093/oncolo/oyag133.

Drugs

Indications